WTCH 24 – Countless historical results and a new superpower emerged
BUDAPEST, Hungary, Dec. 8, 2024 /PRNewswire/ — Every World Teqball Championships is unique in some way, and the 2024 edition was…
Government of Canada supports projects in northern communities to advance gender equality
WHITEHORSE, YT , Dec. 8, 2024 /CNW/ – Women in northern and remote communities face complex challenges that intersect with race,…
The Best Christmas Gift Ideas for 2024: Transformative Skincare with a Special Holiday Twist
PLEASANTON, Calif., Dec. 8, 2024 /PRNewswire/ — This holiday season, DermRays invites you to redefine the spirit of giving with gifts that…
Riyadh Action Agenda Gathers Steam as Land Governance Takes Center Stage at UNCCD COP16
RIYADH, Saudi Arabia, Dec. 8, 2024 /PRNewswire/ — The role of governance in local, regional and international efforts to tackle…
Riyadh International Philosophy Conference 2024 Concludes with a Focus on Quality of Life
Day 3 explored the philosophical contributions to the quality of life, and the ethical implications of AI and its impact…
PRIME MINISTER OF MONGOLIA MAKES HISTORIC VISIT TO MIDDLE EAST
ULAANBAATAR, Mongolia, Dec. 8, 2024 /PRNewswire/ — The Prime Minister of Mongolia, L. Oyun-Erdene, has completed a week-long visit to…
Global Times: Clay Figure Zhang’s works naturally reflect spiritual state of the times
BEIJING, Dec. 7, 2024 /PRNewswire/ — From exquisite craftsmanship to traditional Chinese medicine, from solemn rituals to vibrant folk art,…
University of Nebraska Wins the Abbott and Big Ten Conference’s Nationwide ‘We Give Blood Drive’ Competition, Receives $1 Million Grant from Abbott
Nearly 20,000 Big Ten students, alumni and fans across the country donated blood as part of the Abbott-Big Ten nationwide…
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec.…
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
– 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in…
↑